Can a Three-Drug combo wipe out head and neck tumors before surgery?

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Patients aged ≥18 years; * Males or females who are not pregnant or breastfeeding; * ECOG performance status of 0-1, with no deterioration within the past 7 days; * Patients with histologically confirmed, locally advanced, resectable head and neck squamous cell carcinoma; * Patients who have not previously received any systemic treatment regimens for this cancer type; * Patients receiving neoadjuvant therapy must have evaluable lesions; * Adequate organ and bone marrow function, with laboratory test results meeting the following requirements: 1. HGB ≥ 90 g/L; 2. NEUT ≥ 1.5 × 10⁹/L; 3. PLT ≥ 80 × 10⁹/L; 4. Total bilirubin (TBIL) ≤ 1.5 times the upper limit of normal (ULN); 5. ALT and AST ≤ 2.5 × ULN; in cases of liver metastases, ALT and AST ≤ 5 × ULN; 6. Endogenous creatinine clearance ≥ 50 mL/min (Cockcroft-Gault formula); 7. Urinary protein \< (++), or 24-hour urinary protein \< 1.0 g. * Normal coagulation function with no active bleeding 1. International Normalized Ratio (INR) ≤ 1.5; 2. Activated Partial Thromboplastin Time (APTT) ≤ 1.5 times the upper limit of normal (ULN). * Women of childbearing potential must have a negative pregnancy test (serum or urine) within 14 days prior to enrollment and must voluntarily use appropriate contraception during the observation period and for 8 weeks after the last administration of the study drug; for men, they must be surgically sterilized or agree to use appropriate contraception during the observation period and for 8 weeks after the last administration of the study drug. * Expected survival ≥ 12 months. * Patients must voluntarily enroll in this study and sign an Informed Consent Form (ICF). * Patients are expected to demonstrate good compliance and be able to follow up on efficacy and adverse reactions as required by the protocol. Exclusion Criteria: * Previous receipt of any antitumor therapy for head and neck squamous cell carcinoma; * Administration of a live vaccine within 4 weeks prior to enrollment or likely to occur during the study period; * Active autoimmune disease or a history of autoimmune disease within 4 weeks prior to enrollment; * Previous allogeneic bone marrow or organ transplantation; * Uncontrolled hypertension prior to enrollment, defined as systolic blood pressure ≥160 mmHg and/or diastolic blood pressure ≥90 mmHg; * Any disease or condition prior to enrollment that affects drug absorption; * Clinically significant cardiovascular disease, including but not limited to acute myocardial infarction, severe/unstable angina, or coronary artery bypass grafting within 6 months prior to enrollment; New York Heart Association (NYHA) Class \>2 congestive heart failure; ventricular arrhythmias requiring medication; LVEF (left ventricular ejection fraction) \<50%; * Active or uncontrolled severe infection (≥CTCAE v5.0 Grade 2 infection); 9. Known human immunodeficiency virus (HIV) infection. History of clinically significant liver disease, including viral hepatitis \[known hepatitis B virus (HBV) carriers must be free of active HBV infection, i.e., HBV DNA positive (\>1×10⁴ copies/mL or \>2,000 IU/mL); known hepatitis C virus (HCV) infection with HCV RNA positive (\>1×10³ copies/mL) ; * Any other disease, clinically significant metabolic abnormalities, physical examination abnormalities, or laboratory test abnormalities that, in the investigator's judgment, give reason to suspect that the patient has a condition or state that makes them unsuitable for the study drug (e.g., a history of epileptic seizures requiring treatment), or that will affect the interpretation of study results, or that places the patient at high risk; * Patients whom the investigator deems unsuitable for enrollment in this study.